• Bin Cao, Yi Huang, Dan-Yang She, Qi-Jian Cheng, Hong Fan, Xin-Lun Tian, Jin-Fu Xu, Jing Zhang, Yu Chen, Ning Shen, Hui Wang, Mei Jiang, Xiang-Yan Zhang, Yi Shi, Bei He, Li-Xian He, You-Ning Liu, and Jie-Ming Qu.
• National Clinical Research Center of Respiratory Diseases, Center for Respiratory Diseases, China－Japan Friendship Hospital, Capital Medical University, Beijing 100029, China.
• Clin Respir J. 2018 Apr 1; 12 (4): 1320-1360.

AbstractCommunity-acquired pneumonia (CAP) in adults is an infectious disease with high morbidity in China and the rest of the world. With the changing pattern in the etiological profile of CAP and advances in medical techniques in diagnosis and treatment over time, Chinese Thoracic Society of Chinese Medical Association updated its CAP guideline in 2016 to address the standard management of CAP in Chinese adults. Extensive and comprehensive literature search was made to collect the data and evidence for experts to review and evaluate the level of evidence. Corresponding recommendations are provided appropriately based on the level of evidence. This updated guideline covers comprehensive topics on CAP, including aetiology, antimicrobial resistance profile, diagnosis, empirical and targeted treatments, adjunctive and supportive therapies, as well as prophylaxis. The recommendations may help clinicians manage CAP patients more effectively and efficiently. CAP in pediatric patients and immunocompromised adults is beyond the scope of this guideline. This guideline is only applicable for the immunocompetent CAP patients aged 18 years and older. The recommendations on selection of antimicrobial agents and the dosing regimens are not mandatory. The clinicians are recommended to prescribe and adjust antimicrobial therapies primarily based on their local etiological profile and results of susceptibility testing, with reference to this guideline.© 2017 John Wiley & Sons Ltd.

28 keywords...

hide…